These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36000584)

  • 1. Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.
    Annic J; Babey H; Corre R; Descourt R; Quéré G; Renaud E; Lambert M; Le Noac'h P; Dhamelincourt E; Nguyen J; Vu A; Bourbonne V; Robinet G; Geier M
    Cancer Med; 2023 Feb; 12(3):2658-2665. PubMed ID: 36000584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
    Pasello G; Carli P; Canova F; Bonanno L; Polo V; Zago G; Urso L; Conte P; Favaretto A
    Anticancer Res; 2015 Apr; 35(4):2183-9. PubMed ID: 25862876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
    Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
    Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
    Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
    Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.
    Jacot W; Pujol JL; Chakra M; Molinier O; Bozonnat MC; Gervais R; Quantin X
    Lung Cancer; 2012 Feb; 75(2):213-6. PubMed ID: 21831476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
    Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
    Roussel-Simonin C; Gougis P; Lassoued D; Vozy A; Veyri M; Morardet L; Wassermann J; Foka Tichoue H; Jaffrelot L; Hassani L; Perrier A; Bergeret S; Taillade L; Spano JP; Campedel L; Abbar B
    Acta Oncol; 2023 Jun; 62(6):579-586. PubMed ID: 37276270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Gelsomino F; Tiseo M; Barbieri F; Riccardi F; Cavanna L; Frassoldati A; Delmonte A; Longo L; Dazzi C; Cinieri S; Colantonio I; Sperandi F; Lamberti G; Brocchi S; Tofani L; Boni L; Ardizzoni A
    Br J Cancer; 2020 Jul; 123(1):26-32. PubMed ID: 32346071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
    Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
    Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].
    Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
    Yun T; Kim HT; Han JY; Yoon SJ; Kim HY; Nam BH; Lee JS
    Cancer Res Treat; 2016 Apr; 48(2):465-72. PubMed ID: 26044164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
    Rozzi A; Salerno M; Bordin F; De Marco F; Di Nicola S; Lanzetta G
    Med Oncol; 2011 Dec; 28 Suppl 1():S426-32. PubMed ID: 21116878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
    Jalal S; Bedano P; Einhorn L; Bhatia S; Ansari R; Bechar N; Koneru K; Govindan R; Wu J; Yu M; Schneider B; Hanna N
    J Thorac Oncol; 2010 Dec; 5(12):2008-11. PubMed ID: 21102263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
    Hacibekiroglu I; Ozkul O; Cakir E; Kostek O; Karatas F; Esenkaya A; Demirci A; Bilir C
    J BUON; 2021; 26(1):79-86. PubMed ID: 33721436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
    Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T
    Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.